Amarin (NASDAQ:AMRN) has lost its patent battle against generics.
Shares are down 68% in after hours action.
Developing …
Update: The court found that the
generic firms’ marketing applications will infringe on the asserted
claims of the Amarin patent but added that the asserted claims are
invalid as obvious.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.